Literature DB >> 27717262

Abandoning personalization to get to precision in the pharmacotherapy of depression.

Roy H Perlis1.   

Abstract

Effectiveness studies and analyses of naturalistic cohorts demonstrate that many patients with major depressive disorder do not experience symptomatic remission with antidepressant treatments. In an effort to better match patients with effective treatments, numerous investigations of predictors or moderators of treatment response have been reported over the past five decades, including clinical features as well as biological measures. However, none of these have entered routine clinical practice; instead, clinicians typically personalize treatment on the basis of patient preferences as well as their own. Here, we review the reasons why it has been challenging to identify and deploy treatment-specific predictors of response, and suggest strategies that may be required to achieve true precision in the pharmacotherapy of depression. We emphasize the need for changes in how depression care is delivered, measured, and used to inform future practice.
© 2016 World Psychiatric Association.

Entities:  

Keywords:  Antidepressants; biomarkers; major depression; personalized medicine; precision medicine; risk stratification; treatment matching

Year:  2016        PMID: 27717262      PMCID: PMC5032508          DOI: 10.1002/wps.20345

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  47 in total

1.  Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model.

Authors:  R H Perlis; D V Iosifescu; V M Castro; S N Murphy; V S Gainer; J Minnier; T Cai; S Goryachev; Q Zeng; P J Gallagher; M Fava; J B Weilburg; S E Churchill; I S Kohane; J W Smoller
Journal:  Psychol Med       Date:  2011-06-20       Impact factor: 7.723

2.  The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine.

Authors:  Aimee M Hunter; Ian A Cook; Scott D Greenwald; Melody L Tran; Kate N Miyamoto; Andrew F Leuchter
Journal:  J Clin Neurophysiol       Date:  2011-10       Impact factor: 2.177

Review 3.  Translating biomarkers to clinical practice.

Authors:  R H Perlis
Journal:  Mol Psychiatry       Date:  2011-06-28       Impact factor: 15.992

4.  Variant GADL1 and response to lithium in bipolar I disorder.

Authors:  Chau-Shoun Lee; Andrew Tai-Ann Cheng
Journal:  N Engl J Med       Date:  2014-05-08       Impact factor: 91.245

5.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

6.  Variant GADL1 and response to lithium therapy in bipolar I disorder.

Authors:  Chien-Hsiun Chen; Chau-Shoun Lee; Ming-Ta Michael Lee; Wen-Chen Ouyang; Chiao-Chicy Chen; Mian-Yoon Chong; Jer-Yuarn Wu; Happy Kuy-Lok Tan; Yi-Ching Lee; Liang-Jen Chuo; Nan-Ying Chiu; Hin-Yeung Tsang; Ta-Jen Chang; For-Wey Lung; Chen-Huan Chiu; Cheng-Ho Chang; Ying-Sheue Chen; Yuh-Ming Hou; Cheng-Chung Chen; Te-Jen Lai; Chun-Liang Tung; Chung-Ying Chen; Hsien-Yuan Lane; Tung-Ping Su; Jung Feng; Jin-Jia Lin; Ching-Jui Chang; Po-Ren Teng; Chia-Yih Liu; Chih-Ken Chen; I-Chao Liu; Jiahn-Jyh Chen; Ti Lu; Chun-Chieh Fan; Ching-Kuan Wu; Chang-Fang Li; Kathy Hsiao-Tsz Wang; Lawrence Shih-Hsin Wu; Hsin-Ling Peng; Chun-Ping Chang; Liang-Suei Lu; Yuan-Tsong Chen; Andrew Tai-Ann Cheng
Journal:  N Engl J Med       Date:  2013-12-25       Impact factor: 91.245

7.  Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease.

Authors:  J Scott Roberts; Clara A Chen; Wendy R Uhlmann; Robert C Green
Journal:  Genet Med       Date:  2012-04-12       Impact factor: 8.822

8.  Patient factors associated with SSRI dose for depression treatment in general practice: a primary care cross sectional study.

Authors:  Chris F Johnson; Nadine J Dougall; Brian Williams; Stephen A MacGillivray; Alasdair I Buchanan; Richard D Hassett
Journal:  BMC Fam Pract       Date:  2014-12-24       Impact factor: 2.497

9.  QT interval and antidepressant use: a cross sectional study of electronic health records.

Authors:  Victor M Castro; Caitlin C Clements; Shawn N Murphy; Vivian S Gainer; Maurizio Fava; Jeffrey B Weilburg; Jane L Erb; Susanne E Churchill; Isaac S Kohane; Dan V Iosifescu; Jordan W Smoller; Roy H Perlis
Journal:  BMJ       Date:  2013-01-29

10.  Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression.

Authors:  J Winner; J D Allen; C Anthony Altar; A Spahic-Mihajlovic
Journal:  Transl Psychiatry       Date:  2013-03-19       Impact factor: 6.222

View more
  24 in total

1.  Can we at least learn to fail faster?

Authors:  Gregory E Simon
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

2.  Carving depression at its joints?

Authors:  Allan H Young; Alessandro Colasanti
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

3.  Taking the depressed "person" into account before moving into personalized or precision medicine.

Authors:  Koen Demyttenaere
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

4.  Toward precision medicine for depression: admitting ignorance and focusing on failures.

Authors:  A John Rush
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

5.  Person-centered measurement-based care for depression.

Authors:  Rudolf Uher
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

6.  Pragmatic treatment options for depression and anxiety disorders are needed.

Authors:  Gavin Andrews; Megan J Hobbs
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

7.  Computational Psychiatry: Embracing Uncertainty and Focusing on Individuals, Not Averages.

Authors:  Adam M Chekroud; Chadrick E Lane; David A Ross
Journal:  Biol Psychiatry       Date:  2017-09-15       Impact factor: 13.382

8.  Estimating outcome probabilities from early symptom changes in cognitive therapy for recurrent depression.

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett
Journal:  J Consult Clin Psychol       Date:  2019-04-22

9.  Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing.

Authors:  Zane Zeier; Linda L Carpenter; Ned H Kalin; Carolyn I Rodriguez; William M McDonald; Alik S Widge; Charles B Nemeroff
Journal:  Am J Psychiatry       Date:  2018-04-25       Impact factor: 18.112

10.  Improving Mental Health Services: A 50-Year Journey from Randomized Experiments to Artificial Intelligence and Precision Mental Health.

Authors:  Leonard Bickman
Journal:  Adm Policy Ment Health       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.